In what will be routine announcements going forward, Akebia Therapeutics (NASDAQ:AKBA) and TherapeuticsMD (NASDAQ:TXMD) report that they do not anticipate any disruptions in the availability of their products, at present, due to COVID-19.
TXMD is down 7% premarket on light volume.
https://seekingalpha.com/news/3551946-biotechs-update-on-product-supply-amid-coronavirus-outbreak
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.